睿知中国医院研究地图
候选清单

上海上海交通大学医学院

上海交通大学医学院附属第九人民医院

Shanghai Ninth People's Hospital

在本站收录的 61 种疾病中,这家医院列在其中 27 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

上海交通大学医学院附属第九人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
  3. 肺癌Lung cancer33 篇牵头论文
  4. 胰腺癌Pancreatic cancer11 篇牵头论文
  5. 乳腺癌Breast cancer27 篇牵头论文
  6. 胶质瘤Glioma9 篇牵头论文
  7. 视网膜母细胞瘤Retinoblastoma29 篇牵头论文
  8. 骨肉瘤Osteosarcoma15 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  11. 淋巴瘤Lymphoma22 篇牵头论文牵头 1 项开放试验
  12. 血友病 AHaemophilia A1 篇牵头论文
  13. 范可尼贫血Fanconi anaemia1 篇牵头论文
  14. 冠心病Coronary heart disease15 篇牵头论文
  15. 先天性心脏病Congenital heart disease0 篇牵头论文
  16. 脊柱侧弯Scoliosis2 篇牵头论文
  17. 大动脉炎Takayasu arteritis0 篇牵头论文
  18. 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
  19. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
  20. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  21. 白塞病Behçet disease1 篇牵头论文
  22. IgA 肾病IgA nephropathy0 篇牵头论文
  23. 成骨不全症Osteogenesis imperfecta1 篇牵头论文
  24. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  25. 先天性巨结肠Hirschsprung disease0 篇牵头论文
  26. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa1 篇牵头论文
  27. Leber 遗传性视神经病变Leber hereditary optic neuropathy1 篇牵头论文

未列出的收录疾病:肝细胞癌、胃癌、肝母细胞瘤、脊索瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、法布雷病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、原发性硬化性胆管炎、先天性膈疝、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 0020232024: 0020242025: 002025

上海有 10 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题复发与转移影像与人工智能
论文中的科室耳鼻喉/头颈外科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

上海有 18 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 33 篇,占 0.1%。

牵头论文
33
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 8820222023: 4420232024: 5520242025: 442025

上海有 22 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
    分期
    II期
    开始
    2024-04
    发布
    登记号
    NCT06127303

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海市胸科医院;另有 2 家列出的医院为研究中心上海

  2. 正在招募
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    分期
    I/II期
    开始
    2021-09
    发布
    登记号
    NCT04930432

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 56 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、大连、天津、太原、广州、徐州、成都、昆明、杭州、武汉、汕头、沈阳、济南、深圳、温州、潍坊、烟台、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科眼科/神经眼科

这些论文过半是实验室或动物研究。

牵头的论文33
  1. Social support, health behavior self-efficacy, and anxiety on physical activity levels among lung cancer survivors: a structural equation modeling.2026Journal of cancer survivorship : research and practice
  2. Development of a Machine Learning Algorithm-Based Predictive Model for Physical Activity Levels in Lung Cancer Survivors: A Cross-Sectional Study.2026Journal of clinical nursing
  3. A 7-Year-Old Girl With Multiple Pulmonary Nodules.2025Chest
  4. Analysis of Factors Related to Physical Activity Levels Among Lung Cancer Survivors Who Underwent Nonsurgical Treatment: A Cross-Sectional Study.2025Journal of clinical nursing
  5. A-to-I RNA Edited miR-3167 Restrains Malignant Behaviors of Lung Adenocarcinoma by Influencing SSR2-Meditated Hippo Signaling.2025Molecular carcinogenesis
  6. Evaluation of the risk-benefit of thoracic paravertebral nerve block combined with propofol anesthesia and inhalation combined anesthesia for radical treatment in elderly lung cancer based on diaphragm functional parameters.2025Pakistan journal of pharmaceutical sciences
  7. Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.2024BMC cancer免费全文
  8. Tumor-Derived RAB21+ABHD12+ sEVs Drive the Premetastatic Microenvironment in the Lung.2024Cancer immunology research
  9. SNHG12 in cancer-associated fibroblast-derived extracellular vesicle induces macrophage-myofibroblast transition.2024Epigenomics免费全文
  10. Nasal mRNA Nanovaccine with Key Activators of Dendritic and MAIT Cells for Effective Against Lung Tumor Metastasis in Mice Model.2024International journal of nanomedicine免费全文
  11. Exploring factors associated with postoperative physical activity and sedentary behavior in newly diagnosed lung cancer patients: a cross-sectional study.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  12. LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP.2023Annals of clinical and laboratory science
  13. Combined all-trans retinoic acid with low-dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single-center, secondary analysis of a phase II study.2023Cancer medicine免费全文
  14. TRAIP serves as a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.2023International immunopharmacology
  15. Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency.2023Theranostics免费全文
  16. Exosomes from PM 2.5-treated Human Bronchial Epithelial Cells Increase Lung Cancer Metastatic Potential.2022Biomedical and environmental sciences : BES
  17. circBIRC6 contributes to the development of non-small cell lung cancer via regulating microRNA-217/amyloid beta precursor protein binding protein 2 axis.2022Chinese medical journal免费全文
  18. Skin Metastasis: Rare First Manifestation of Lung Cancer.2022Facial plastic surgery : FPS
  19. Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation.2022Frontiers in endocrinology免费全文
  20. Fbxo45-mediated NP-STEP46 degradation via K6-linked ubiquitination sustains ERK activity in lung cancer.2022Molecular oncology免费全文
  21. Development of mobile health-based self-management support for patients with lung cancer: A stepwise approach.2022Nursing open免费全文
  22. ALK-fusion-positive secondary ameloblastic carcinoma reached complete response after using alectinib.2022Oral oncology
  23. HIF-1α induced NID1 expression promotes pulmonary metastases via the PI3K-AKT pathway in salivary gland adenoid cystic carcinoma.2022Oral oncology
  24. The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis.2021Aging免费全文
  25. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants.2021Cancer biology & medicine免费全文
  26. Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer.2021Cancer letters
  27. LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.2021Cancer letters
  28. Lactate secreted by PKM2 upregulation promotes Galectin-9-mediated immunosuppression via inhibiting NF-κB pathway in HNSCC.2021Cell death & disease免费全文
  29. MRI Image Segmentation Model with Support Vector Machine Algorithm in Diagnosis of Solitary Pulmonary Nodule.2021Contrast media & molecular imaging免费全文
  30. Intranasal Administration of Codium fragile Polysaccharide Elicits Anti-Cancer Immunity against Lewis Lung Carcinoma.2021International journal of molecular sciences免费全文
  31. ESM1/HIF‑1α pathway modulates chronic intermittent hypoxia‑induced non‑small‑cell lung cancer proliferation, stemness and epithelial‑mesenchymal transition.2021Oncology reports
  32. Chondroitin sulfate modified and adriamycin preloaded hybrid nanoparticles for tumor-targeted chemotherapy of lung cancer.2021The Kaohsiung journal of medical sciences免费全文
  33. The reversal of drug resistance by two-dimensional titanium carbide Ti2 C (2D Ti2C) in non-small-cell lung cancer via the depletion of intracellular antioxidant reserves.2021Thoracic cancer免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC正在招募NCT06127303研究中心II期2024-04 启动
  2. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors正在招募NCT04930432研究中心I/II期2021-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.2%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 3320222023: 2220232024: 1120242025: 112025

上海有 19 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胰腺癌开放试验。

这些数字背后的记录
论文中的科室放疗科病理/检验科影像/核医学科消化/肝病科
牵头的论文11
  1. OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer.2025Nature communications免费全文
  2. ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7.2024International journal of biological sciences免费全文
  3. A case report of huge pancreas mucinous cystic neoplasm during pregnancy: How doctors think.2023Medicine
  4. PTTG1 Enhances Oncolytic Adenovirus 5 Entry into Pancreatic Adenocarcinoma Cells by Increasing CXADR Expression.2023Viruses免费全文
  5. Modulating cancer-stroma crosstalk by a nanoparticle-based photodynamic method to pave the way for subsequent therapies.2022Biomaterials
  6. METTL3 promotes the growth and metastasis of pancreatic cancer by regulating the m6A modification and stability of E2F5.2022Cellular signalling
  7. Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.2022Gut
  8. Pancreatic tuberculosis: a clinical diagnostic challenge.2021ANZ journal of surgery
  9. lncRNA ANRIL aggravates the chemoresistance of pancreatic cancer cells to gemcitabine by targeting inhibition of miR-181a and targeting HMGB1-induced autophagy.2021Aging免费全文
  10. The RNA methyltransferase NSUN6 suppresses pancreatic cancer development by regulating cell proliferation.2021EBioMedicine免费全文
  11. Formulation Comprising Arsenic Trioxide and Dimercaprol Enhances Radiosensitivity of Pancreatic Cancer Xenografts.2021Technology in cancer research & treatment免费全文

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.2%。

牵头论文
27
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 111120222023: 6620232024: 1120242025: 442025

上海有 19 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    分期
    II期
    开始
    2023-12
    发布
    登记号
    NCT06107686

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南宁、南昌、台州、合肥、哈尔滨、太原、广州、徐州、成都、杭州、桂林、梅州、武汉、汕头、沈阳、济南、潍坊、苏州、襄阳、西安、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室放疗科普外/肝胆胰外科病理/检验科肿瘤内科
牵头的论文27
  1. Prognostic significance of CD8 + tumor-infiltrating lymphocytes in operable breast cancer: a meta-analysis.2025BMC cancer免费全文
  2. Effects of sufentanil on immune response, pain mediators and brain-sparing effect in patients with breast cancer undergoing radical mastectomy.2025BMC surgery免费全文
  3. Adipose-derived stem cells enhance the tumorigenic potential of pre-malignant breast epithelial cells through paracrine activation of PI3K-AKT pathway.2025Breast cancer (Tokyo, Japan)免费全文
  4. Combining ultrasound gray scale ratio and BI-RADS grading for differentiating benign and malignant breast masses.2025Clinical hemorheology and microcirculation
  5. Unlocking the potential of extracellular vesicle circRNAs in breast cancer: From molecular mechanisms to therapeutic horizons.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  6. Medical Insurance Needs to Include Breast Reconstruction.2023Annals of plastic surgery
  7. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.2023Breast (Edinburgh, Scotland)免费全文
  8. Integrative pan-cancer analysis of cuproplasia-associated genes for the genomic and clinical characterization of 33 tumors.2023Chinese medical journal免费全文
  9. The prognostic value and biological functions of HFM1 in breast cancer.2023Epigenomics
  10. Comparative Proteomic Analysis of Irradiation-Induced Radioresistant Breast Cancer Cells Using Label-Free Quantitation.2023Frontiers in bioscience (Landmark edition)
  11. Detection of lineage-reprogramming efficiency of tumor cells in a 3D-printed liver-on-a-chip model.2023Theranostics免费全文
  12. Efficient Magnetic Nanocatalyst-Induced Chemo- and Ferroptosis Synergistic Cancer Therapy in Combination with T1-T2 Dual-Mode Magnetic Resonance Imaging Through Doxorubicin Delivery.2022ACS applied materials & interfaces
  13. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.2022Clinical drug investigation
  14. A comprehensive bioinformatic analysis of RanBP9 expression and its relation to prognosis in human breast cancer.2022Epigenomics
  15. Landscape of Artificial Intelligence in Breast Cancer (2000-2021): A Bibliometric Analysis.2022Frontiers in bioscience (Landmark edition)
  16. Association of Adiposity With Mortality Among Black Patients With Breast Cancer.2022JAMA oncology
  17. Atypical/unbalanced ETV6/NTRK3 rearrangement in salivary secretory carcinoma with a focus on the incidence, the patterns, and the clinical implications.2022Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  18. TRIM35 functions as a novel tumor suppressor in breast cancer by inducing cell apoptosis through ubiquitination of PDK1.2022Neoplasma
  19. Anterior Gradient 2 is a Significant Prognostic Biomarker in Bone Metastasis of Breast Cancer.2022Pathology oncology research : POR免费全文
  20. Comment on: Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis.2022The British journal of surgery
  21. Exploring the Value of Additional Primary Tumour Excision Combined with Systemic Therapy Administered in Different Sequences for Patients with de Novo Metastatic Breast Cancer.2022The breast journal免费全文
  22. Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.2022World journal of surgical oncology免费全文
  23. Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.2021Frontiers in public health免费全文
  24. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.2021Journal of nanobiotechnology免费全文
  25. Graphene-modified CePO4 nanorods effectively treat breast cancer-induced bone metastases and regulate macrophage polarization to improve osteo-inductive ability.2021Journal of nanobiotechnology免费全文
  26. Mindfulness-based interventions for breast cancer patients in China across outcome domains: a systematic review and meta-analysis of the Chinese literature.2021Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  27. Application of a second opinion ultrasound in Breast Imaging Reporting and Data System 4A cases: can immediate biopsy be avoided?2021The Journal of international medical research免费全文
中文论文(未计入)1
  1. [Effectiveness of lobulated pedicled rectus abdominis myocutaneous flap for repairing huge chest wall defect].2023Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. A Study of YL202 in Selected Patients With Advanced Solid Tumors正在招募NCT06107686研究中心II期2023-12 启动
  2. Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors状态不明NCT05145907研究中心II期2021-12 启动
  3. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  4. Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors状态不明NCT04450732研究中心I期2020-07 启动
  5. Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer已完成NCT03856372研究中心不分期2018-09 启动
  6. Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer进行中,不再招募NCT02455141研究中心III期2016-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胶质瘤

Glioma

2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 9 篇,占 0.1%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 4420242025: 222025

上海有 17 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科神经外科眼科/神经眼科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 29 篇,占 9.6%。

牵头论文
29
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 6620222023: 5520232024: 6620242025: 882025

上海有 11 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科
牵头的论文29
  1. Status of and factors influencing paternal fatigue in children with retinoblastoma: a cross-sectional study.2025BMC cancer免费全文
  2. Factors influencing delayed medical treatment in children with retinoblastoma: a qualitative study.2025BMC cancer免费全文
  3. Anxiety, depression and fear of disease progression among Chinese parents of children with retinoblastoma.2025BMC psychiatry免费全文
  4. Lactylation-boosted polycomb repression of KLF4 elicits glycolysis in retinoblastoma: A positive feedback circuit between histone modifications.2025Cancer letters
  5. Spatial Proteomic Analysis Highlights Molecular Reprogramming in Optic Nerve Invasive Retinoblastoma.2025Investigative ophthalmology & visual science免费全文
  6. Aurora A Kinase Inhibition Is Synthetic Lethal With the Activation of MYCN in Retinoblastoma.2025Investigative ophthalmology & visual science免费全文
  7. Increased clinical risk factors and absence of leucocoria in late-onset retinoblastoma: a comparative cohort study.2025The British journal of ophthalmology
  8. Effect of intra-arterial chemotherapy drug regimens on globe salvage outcomes of retinoblastoma patients.2025The British journal of ophthalmology免费全文
  9. Does vitreous haemorrhage and calcification lead to increased risk of enucleation in advanced retinoblastoma?2024Acta ophthalmologica
  10. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management.2024Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
  11. Hemostatic effect of 3D-printed hip fixators in children with retinoblastoma after intra-arterial chemotherapy: a non-randomized controlled trial.2024Scientific reports免费全文
  12. Factors influencing parental fatigue in children with retinoblastoma based on the unpleasant symptoms theory.2024Scientific reports免费全文
  13. Risk factors for cataract in retinoblastoma management.2024The British journal of ophthalmology免费全文
  14. Correlating somatic copy number alteration in aqueous humour cfDNA with chemotherapy history, eye salvage and pathological features in retinoblastoma.2024The British journal of ophthalmology免费全文
  15. NSUN2-mediated m5 C RNA methylation dictates retinoblastoma progression through promoting PFAS mRNA stability and expression.2023Clinical and translational medicine免费全文
  16. Human Papillomavirus and Retinoblastoma: Evidence From a Systematic Review and Meta-analysis of Cross-Sectional Studies.2023International journal of public health免费全文
  17. The Use of rAAV2-RB1-Mediated Gene Therapy in Retinoblastoma.2023Investigative ophthalmology & visual science免费全文
  18. A novel MYCN-YTHDF1 cascade contributes to retinoblastoma tumor growth by eliciting m6A -dependent activation of multiple oncogenes.2023Science China. Life sciences
  19. Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial.2023The Lancet. Child & adolescent health
  20. Contemporary Update of Retinoblastoma in China: Three-Decade Changes in Epidemiology, Clinical Features, Treatments, and Outcomes.2022American journal of ophthalmology
  21. Novel insights into RB1 mutation.2022Cancer letters
  22. Eye-Preserving Therapies for Advanced Retinoblastoma: A Multicenter Cohort of 1678 Patients in China.2022Ophthalmology
  23. Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma.2022Progress in retinal and eye research
  24. Monitoring Retinoblastoma by Machine Learning of Aqueous Humor Metabolic Fingerprinting.2022Small methods
  25. Risk factors for ophthalmic artery stenosis and occlusion in patients with retinoblastoma treated with intra-arterial chemotherapy.2022The British journal of ophthalmology免费全文
  26. Hope level and associated factors among parents of retinoblastoma patients during COVID-19 pandemic: a cross-sectional study.2021BMC psychiatry免费全文
  27. Single-cell transcriptome profiling reveals intratumoural heterogeneity and malignant progression in retinoblastoma.2021Cell death & disease免费全文
  28. Clinical characteristics and germline mutation spectrum of RB1 in Chinese patients with retinoblastoma: A dual-center study of 145 patients.2021Experimental eye research
  29. Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle.2021Investigative ophthalmology & visual science免费全文
中文论文(未计入)1
  1. [Metachronous bilateral retinoblastoma: a case report].2024[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
早期论文(2016–2020 年)4
  1. LncRNA CANT1 suppresses retinoblastoma progression by repellinghistone methyltransferase in PI3Kγ promoter.2020Cell death & disease
  2. A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F3.2020Molecular cancer
  3. Dynamic chromosomal tuning of a novel GAU1 lncing driver at chr12p13.32 accelerates tumorigenesis.2018Nucleic acids research
  4. [Pay attention to the application of the international intraocular retinoblastoma classification and sequential multiple modality treatment].2017[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma状态不明NCT04990271研究中心II期2021-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.7%。

牵头论文
15
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 4420232024: 3320242025: 442025

上海有 45 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文15
  1. Tumor microenvironment-activated ROS enhancers for effective inhibition of osteosarcoma.2025BMC biotechnology免费全文
  2. Malignant transformation of craniofacial fibrous dysplasia: A clinicopathological, immunohistochemical and molecular analysis of 15 cases in one single institution.2025Journal of stomatology, oral and maxillofacial surgery
  3. Nanohydroxyapatite-Stabilized Pickering-Emulsion-Incorporated Hydrogel Prevents Postoperative Osteosarcoma Recurrence and Promotes Bone Repair.2025Nano letters
  4. Prognostic factors of head and neck osteosarcoma: A 10-year retrospective study from a single institute.2025Oral oncology
  5. Photothermal-Triggered Extracellular Matrix Clearance and Dendritic Cell Maturation for Enhanced Osteosarcoma Immunotherapy.2024ACS applied materials & interfaces
  6. Head and Neck Osteosarcoma: Perineural Invasion is Associated With Disease-Free Survival and Tumor Metastasis.2024Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  7. Real-world impact of chemotherapy on overall survival in craniomaxillofacial osteosarcoma.2024Journal of stomatology, oral and maxillofacial surgery
  8. DDRGK1 Enhances Osteosarcoma Chemoresistance via Inhibiting KEAP1-Mediated NRF2 Ubiquitination.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  9. EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis.2023Biomolecules免费全文
  10. Osteosarocma progression in biomimetic matrix with different stiffness: Insights from a three-dimensional printed gelatin methacrylamide hydrogel.2023International journal of biological macromolecules
  11. Secreted phosphoprotein 24 kD (Spp24) inhibits the growth of human osteosarcoma through the BMP-2/Smad signaling pathway.2023Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  12. Camouflage orthodontic treatment combined with genioplasty distraction osteogenesis for skeletal class II relationship secondary to osteosarcoma excision surgery.2022Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.]
  13. Ultrathin 2D Inorganic Ancient Pigment Decorated 3D-Printing Scaffold Enables Photonic Hyperthermia of Osteosarcoma in NIR-II Biowindow and Concurrently Augments Bone Regeneration.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  14. Polydopamine-coated UiO-66 nanoparticles loaded with perfluorotributylamine/tirapazamine for hypoxia-activated osteosarcoma therapy.2021Journal of nanobiotechnology免费全文
  15. FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.2021Oncogene
中文论文(未计入)1
  1. [Clincopathological analysis of 171 patients with osteochondroma and malignant transformation in maxillofacial bone].2024Shanghai kou qiang yi xue = Shanghai journal of stomatology
早期论文(2016–2020 年)22
  1. Diffusion Kurtosis Imaging as a Prognostic Marker in Osteosarcoma Patients with Preoperative Chemotherapy.2020BioMed research international
  2. A population-based propensity-matched study of regional dissections in patients with metastatic osteosarcoma.2020Journal of orthopaedic surgery and research
  3. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.2019Anticancer research
  4. SNHG16 promotes osteosarcoma progression and enhances cisplatin resistance by sponging miR-16 to upregulate ATG4B expression.2019Biochemical and biophysical research communications
  5. HDAC2-mediated upregulation of IL-6 triggers the migration of osteosarcoma cells.2019Cell biology and toxicology
  6. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.2019Cell death & disease
  7. Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.2019Clinical epigenetics
  8. Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway.2019Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  9. Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma.2018Cell cycle (Georgetown, Tex.)
  10. CXCR1/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis.2018Cell death & disease
  11. Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.2018Current drug targets
  12. MiR-127-3p inhibits cell growth and invasiveness by targeting ITGA6 in human osteosarcoma.2018IUBMB life
  13. Baicalin induces apoptosis in human osteosarcoma cell through ROS-mediated mitochondrial pathway.2018Natural product research
  14. The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity.2017European review for medical and pharmacological sciences
  15. Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival.2017Oral oncology
  16. Dryofragin inhibits the migration and invasion of human osteosarcoma U2OS cells by suppressing MMP-2/9 and elevating TIMP-1/2 through PI3K/AKT and p38 MAPK signaling pathways.2016Anti-cancer drugs
  17. Tectorigenin inhibits osteosarcoma cell migration through downregulation of matrix metalloproteinases in vitro.2016Anti-cancer drugs
  18. Post-operative hemimaxillectomy rehabilitation using prostheses supported by zygoma implants and remaining natural teeth.2016Clinics (Sao Paulo, Brazil)
  19. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.2016Oncotarget
  20. Osteosarcoma of head and neck: A retrospective study on prognostic factors from a single institute database.2016Oral oncology
  21. Osteosarcoma of the Mandible: A Site-Specific Study on Survival and Prognostic Factors.2016The Journal of craniofacial surgery
  22. TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

上海有 21 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

上海有 27 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.6%。

牵头论文
22
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 4420222023: 6620232024: 5520242025: 222025

上海有 20 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
    分期
    II期
    开始
    2023-11
    发布
    登记号
    NCT06503276

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属第九人民医院上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室眼科/神经眼科病理/检验科影像/核医学科肿瘤内科
牵头的论文22
  1. A Stepwise decision tree model for differential diagnosis of Kimura's disease in the head and neck.2025BMC medical imaging免费全文
  2. Serum metabolic patterns reveal the diagnostic and prognostic role of alanine abnormality in ocular adnexal lymphoma.2025Proceedings of the National Academy of Sciences of the United States of America免费全文
  3. Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.2024Bone marrow transplantation
  4. Prediction model of radiotherapy outcome for Ocular Adnexal Lymphoma using informative features selected by chemometric algorithms.2024Computers in biology and medicine
  5. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.2024Leukemia免费全文
  6. A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.2024Lipids in health and disease免费全文
  7. Prognostic factors and clinical survival outcome in patients with primary mediastinal diffuse large B-cell lymphoma in rituximab era: A population-based study.2024Medicine免费全文
  8. MYC-targeted genes predict distant recurrence in patients with ocular adnexal extranodal marginal zone lymphoma.2023Annals of hematology
  9. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.2023Cell transplantation免费全文
  10. Multi-omics and case-control analyses identify immunoglobulin M as a tumour-derived serum biomarker of ocular adnexal extranodal marginal zone lymphoma.2023Clinical and translational medicine免费全文
  11. Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.2023International journal of molecular sciences免费全文
  12. MALT lymphoma of the head and neck: Surgery alone can be an option.2023Oral oncology
  13. Predicting the risk of distant and local recurrence for patients with ocular adnexal extranodal marginal zone lymphoma: a matched case-control study.2023The British journal of ophthalmology
  14. Loss of LEF-1 expression as a diagnostic indicator for extranodal NK/T-cell lymphoma: An immunohistochemical study of 88 cases.2022European journal of haematology
  15. Proteotranscriptomics of ocular adnexal B-cell lymphoma reveals an oncogenic role of alternative splicing and identifies a diagnostic marker.2022Journal of experimental & clinical cancer research : CR免费全文
  16. Conservative treatment of head and neck lymphoma is not the only effective treatment: A retrospective analysis of 301 cases.2022Oral oncology
  17. A retrospective study to evaluate the CT and MR imaging findings of non-Hodgkin's lymphoma affecting the jaw bones.2022Oral radiology
  18. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.2021Aging免费全文
  19. Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.2021Bioscience reports免费全文
  20. Indicators for Malignant Transformation in Patients With Lymphoepithelial Lesion.2021Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  21. Clinicopathological aspects of primary mucosa-associated lymphoid tissue lymphoma of the salivary gland: A retrospective single-center analysis of 72 cases.2021Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  22. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.2021Leukemia research
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy正在招募NCT06503276牵头方II期2023-11 启动
  2. GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma已完成NCT02733458研究中心不分期2016-03 启动
  3. MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma已完成NCT02764281研究中心不分期2015-04 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

上海有 9 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

上海有 4 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.3%。

牵头论文
15
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 2220222023: 1120232024: 4420242025: 222025

上海有 17 家医院列在冠心病下全国有 231 家医院列在冠心病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的冠心病开放试验。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科
牵头的论文15
  1. Long-term changes in frailty and incident atrial fibrillation, heart failure, coronary heart disease, and stroke: A prospective follow-up study.2025Heart rhythm
  2. Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study.2025Scientific reports免费全文
  3. Drug-coated balloon therapy for in-stent restenosis in patients with iliofemoral deep vein thrombosis: A single-arm observational study.2024Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  4. Differences in the Fat Attenuation Index Ratio of Pericoronary Adipose Tissue And Aortic Root Epicardial Adipose Tissue in Various Plaques.2024Current medical imaging
  5. A Mendelian Randomisation Analysis Reveals No Relationship Between Periodontitis and Coronary Atherosclerosis.2024International dental journal免费全文
  6. Analysis of correlative factors of female coronary slow-flow phenomenon: A retrospective study.2024Medicine免费全文
  7. A comparative study of two single-stage oral mucosal substitution urethroplasty (Kulkarni and Asopa) in the surgical treatments of lichen sclerosus urethral strictures.2023Asian journal of andrology免费全文
  8. Joint exposure to positive affect, life satisfaction, broad depression, and neuroticism and risk of cardiovascular diseases: A prospective cohort study.2022Atherosclerosis
  9. Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease.2022BMC cardiovascular disorders免费全文
  10. Nicotine exacerbates atherosclerosis through a macrophage-mediated endothelial injury pathway.2021Aging免费全文
  11. Serum free fatty acids are associated with severe coronary artery calcification, especially in diabetes: a retrospective study.2021BMC cardiovascular disorders免费全文
  12. Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.2021European heart journal
  13. Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity.2021Lipids in health and disease免费全文
  14. Predictive and prognostic value of v-set and transmembrane domain-containing 1 expression in monocytes for coronary artery disease.2021Reviews in cardiovascular medicine
  15. Association of Circulating Irisin Levels and the Characteristics and Prognosis of Coronary Artery Disease.2021The American journal of the medical sciences
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults状态不明NCT02496858研究中心2017-05 启动
  2. Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)状态不明NCT02448524研究中心III期2015-07 启动
  3. Acarbose Cardiovascular Evaluation Trial已完成NCT00829660研究中心IV期2009-02 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年没有牵头先天性心脏病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 19 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊柱侧弯

Scoliosis

2021–2025 年中国大陆作者发表的 925 篇脊柱侧弯 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

上海有 12 家医院列在脊柱侧弯下全国有 107 家医院列在脊柱侧弯下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的脊柱侧弯开放试验。

这些数字背后的记录
牵头的论文2
  1. Clinical features and surgical treatments of scoliosis in neurofibromatosis type 1: a systemic review and meta-analysis.2024European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  2. Teaching NeuroImage: Clinical and Imaging Features of Cobb Syndrome.2024Neurology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 8 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Aneurysms in Takayasu's arteritis: a retrospective study of Chinese patients.2020Clinical and experimental rheumatology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

上海有 26 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 6 家医院列在脊髓性肌萎缩症下全国有 49 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

上海有 11 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

上海有 14 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 23 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. miR-200bc/429 cluster alleviates inflammation in IgA nephropathy by targeting TWEAK/Fn14.2017International immunopharmacology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

上海有 6 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 16 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年没有牵头先天性巨结肠的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 5 家医院列在先天性巨结肠下全国有 76 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
早期论文(2016–2020 年)2
  1. A homozygous MITF mutation leads to familial Waardenburg syndrome type 4.2019American journal of medical genetics. Part A
  2. Genetic analysis of a Chinese family with members affected with Usher syndrome type II and Waardenburg syndrome type IV.2017International journal of pediatric otorhinolaryngology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

上海有 7 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

上海有 3 家医院列在Leber 遗传性视神经病变下全国有 30 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

上海交通大学医学院附属第九人民医院

Shanghai Ninth People's Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Suzhou Ninth People's Hospital; Ninth People's Hospital of Chongqing; Chongqing Ninth People's Hospital; Suzhou Ninth People's Hospital Affiliated to Soochow University; Huangpu Branch of the Ninth People's Hospital; Hangzhou Ninth People's Hospital; Bethel Hospital; 上海第九人民医院

提出更正下载数据